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Abstract 
When an innovative product (innovator) is not covered anymore by intellectual 
property rights, cheaper equivalent medicinal products (generic products) may 
be marketed and used in clinical practice. The regulation of generic products  
is well-established, and is primarily based on standard rules for quality, 
therapeutic equivalence requirements (the latter in most instances proven 
through a bioequivalence study), and safety data for the innovator. The 
extensive experience from bringing generic products to the market over the last 
decades allows the conclusion that they are well-accepted and provide a useful 
alternative option for cost-effective pharmacotherapy. While supporting this 
conclusion, there are a number of issues to be considered during the 
assessment of a generic product application. Six scenarios are described in 
total, from an efficacy and a safety perspective, where potential concerns with 
the current regulatory standards could arise in the approval of generic products. 
We also propose solutions to these scenarios in order to foster debate on these 
issues. 
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Introduction 
During the lifecycle of a medicine, there is constant change and updating of relevant 
features and information. The examination of a medicinal product is never finished and 
continues throughout its lifecycle. When an innovator product is not covered anymore by 
intellectual property rights, such as a patent/supplementary protection certificate or data 
protection granted by the marketing authorization (“off-patent” products), competing 
products containing the same active substance[s] (“generics”) may enter the market and 
clinical practice [1]. The extensive experience gained by the authorization and marketing of 
generics over the last decades allows the conclusion that generic medicinal products are 
well-accepted. As generics are usually cheaper, often substantially, insurers and 
healthcare payers in general tend to encourage their prescription and substitution in place 
of the innovator product. Medicinal product regulators (including all EU national regulatory 
agencies and the US Food and Drug Administration (FDA)) consider generic and branded 
drugs to be therapeutically equivalent if they are pharmaceutically equivalent and 
bioequivalent. However, the American Academy of Neurology disagrees and opposes 
generic substitution of branded antiepileptic drugs without physician and patient approval 
due to the risk of loss of seizure control [2]. Thus, we asked the question, “could there be a 
potential concern with the rules used to approve generics?” 
The regulation of generic products is well-established, and it is primarily based on 
standard rules for the determination of quality, safety, and efficacy (in most instances 
proven through a bioequivalence study) [1, 3]. In the EU, a generic medicinal product is a 
medicinal product which has the same qualitative and quantitative composition in active 
substances and the same pharmaceutical form as the reference medicinal product (the 
innovator), and whose bioequivalence with the reference medicinal product has been 
demonstrated by appropriate bioavailability studies, thus supporting equivalent efficacy, 
unless the requirements for a Biowaiver have been satisfactorily fulfilled [3]. In this paper, 
we discuss potentially clinically relevant scenarios that impact prescription and patient 
treatment that could arise when generics are approved with the current standard rules [3].  
For the sake of clarity, readers should be aware that in a marketing authorisation 
application of a generic medicinal product, data on the interchangeability of generics with 
reference products or other products on the market is not part of a dossier submitted to 
obtain a marketing authorisation. Substitution therapy varies between EU member states 
and is regulated at a national level by each member state.  
Results  
Efficacy and Safety Challenges 
An indication for a medicinal product (product B) still under patent is applied for (this could 
either be as an initial marketing authorisation or as a variation to the marketing 
authorisation). The clinical data package supporting the new indication would include a 
non-inferiority trial, intended to demonstrate that the clinical effect of product B is not 
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inferior to that of an active control (product A) by more than a specified margin [4]. While it 
may not be feasible to include a (third) placebo arm, for example due to ethical reasons 
(products to treat cancer, cardiovascular diseases, epilepsy, etc.), nevertheless, a non-
inferiority clinical trial may still be acceptable. For example, product B could have benefits 
such as a more convenient dosing regimen or route of administration (e.g. oral instead of 
intramuscular), or better tolerability, or a potential small increase in efficacy (which would 
require a larger, more costly superiority trial to be demonstrated). However, there is a 
concern that this may not be sufficiently considered during the subsequent evaluation of a 
generic medicinal product (product C) of product B. As bioequivalence and non-inferiority 
trials are specific subtypes of equivalence trials, a specific type of bio-creep can arise 
here. If the bioavailability of product C is in the lower region of the acceptable range, and 
product B was declared non-inferior, but had slightly less efficacy than that of product A, 
then we cannot safely assume that product C will have similar efficacy to that of product A. 
In other words, bioequivalence of C to B would not guarantee non-inferiority of C to A, 
even if B is non-inferior to A.  
An innovative medicinal product is indicated as monotherapy in the treatment of partial-
onset seizures or other epilepsy indications. The active substance exhibits non-linear 
pharmacokinetics, but also has a wide therapeutic index (i.e. the dose producing a clinical 
effect and the dose producing an adverse event is wide), while the effective dosing range 
for this product is narrow. As the active substance has a wide therapeutic index, the 
conventional 90% confidence interval (CI) limits of 80–125% can be applied here; 
however, they may not be appropriate in this case: if the bioavailability of the generic is 
close to the lower acceptance limit, a supposedly equivalent dose of the generic could well 
lie outside the clinically effective range for the specific therapeutic indication. This could 
potentially translate into a significant risk of a breakout seizure that may have serious 
consequences depending on what activity the patient is doing at that precise point in time. 
This mechanism might have been involved in the case reports of the loss of seizure  
control with what authors reported as “generics” (drugs reported include phenytoin, 
carbamazepine, valproic acid, lamotrigine, levetiracetam, and topiramate) [5–14].  
In the progression of Parkinson’s disease (PD) from early PD through moderate and then 
advanced PD, it is known that the margin of separation between the apparently safe and 
effective dose for medicinal products indicated in PD and the dose causing adverse events 
decreases as PD progresses. Whereby the basic equivalent dose of levodopa / 
benserazide in early PD would result in a smooth prolonged duration of a clinical response 
associated with a low likelihood of dyskinesias, in the case of advanced PD, one would 
tend to observe a short duration of the targeted clinical response “on time” associated with 
dyskinesias. Again, the conventional bioequivalence limits (80–125%) are considered 
appropriate for the approval of a generic product intended to be used during the initial 
phases of the disease, but this might not hold true for the later phases of the disease, 
when the therapeutic index becomes narrower. Then the generic with a higher 
pharmacokinetic exposure (i.e. Cmax and AUC ratios that are higher than 100%), but still 
within the limits of bioequivalence, may not be able to guarantee the same therapeutic 
safety of the reference product [15–17].  
The efficacy of a medicinal product is affected by several factors, including interactions 
with other medicines and genetic variability. In the case of clopidogrel, genetic variations of 
the CYP2C19 enzyme or concomitant use of drugs that inhibit this enzyme, such as proton 
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pump inhibitors [18], introduce variability in the efficacy of clopidogrel. This became known 
several years after the placement of both products on the market.  
A concern on the clinical effectiveness and safety of a generic clopidogrel might arise if the 
confidence interval is close to the lower acceptance limit. Obviously, this concern would be 
even more marked for a highly variable drug. Clopidogrel is not considered a highly 
variable drug; however, an intra-subject variability of 30% has been published in European 
public assessment reports [18]. The EU’s bioequivalence guideline [3] offers the possibility 
to widen the confidence intervals for highly variable drugs. While this is understandable 
and justified from a pharmacokinetic point of view, it could hypothetically in some cases 
raise additional issues of clinical effectiveness / safety. This is because of the possibility 
that drug-drug interactions which have not yet been identified or if the product is affected 
by genetic variability modifying the product’s clinical efficacy.  
A challenge during the approval process of generics is when Risk Minimization Measures 
(RMMs e.g. patient alert cards and educational materials) have been introduced by the 
brand leader on a voluntary basis, but the safety concerns of the reference product are 
briefly mentioned in its labelling without contraindications or specific warnings. In this 
scenario, a generic product can contribute to building the safety profile of the medicine by 
increasing patient exposure. However, it may not be considered appropriate to set legally 
binding obligations in the marketing authorization and to impose RMMs on a generic when 
the reference product lacks these legal obligations [20, 21].  
The approval of a generic product containing two strengths that make reference to 
different reference products (Zometa® and Aclasta® (both contain zolendronic acid)), 
within the same global marketing authorization, could also be challenging. This is because 
both reference products have different educational materials highlighting important 
identified risks, one dealing with the osteonecrosis of the jaw (Zometa®), and the other for 
renal dysfunction (Aclasta®). However, the educational materials implemented for 
Zometa® are voluntary, while those for Aclasta® are obligatory. It should be pointed out 
that the risks of Zometa® and Aclasta® are not the same (since the target patient 
populations differ) and there are differences in the labelling of both products. Thus, the 
assessment of the generic medicinal product should be able to harmonise the product 
information, but neither undermine the results of the evaluation of the reference product, 
nor disregard the important identified risks and the respective educational materials 
[22, 23]. 
Inspection and Enforcement Challenges 
EU regulators rely on the data and analysis of the results from clinical trials which were 
carried out by applicants in order to reach their opinions / recommendations on the 
approval / authorisation of medicines. It implies, therefore, that there is an element of trust 
between regulators and pharmaceutical companies. The system is based on trust. It is 
known that authorities have finite inspectional resources and they cannot inspect all the 
parties that are involved in conducting or overseeing research. It is of great concern when 
questions about the validity of the data in the dossiers are raised, because it gives the 
perception that fabrication of data is easy [24]. Thus, so much depends on a good 
inspection system for clinical practices (GCP) as well as for manufacturing practices 
(GMP). The remit of the EMA’s GCP Inspectors Working Group focuses on the 
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harmonisation and coordination of GCP-related activities at a community level. Bilaterally, 
the EMA and FDA have signed an agreement to join forces to manage the finite resources, 
but this has not extended yet to carrying out joint inspections [25]. Internationally, the 
World Health Organization Prequalification of Medicines Programme (WHO-PQ) 
coordinates the evaluation and inspection activities of submitted finished pharmaceutical 
products for pre-qualification. The inspections are performed by a team of inspectors 
consisting of experts appointed by the WHO (preferably from drug regulatory authorities' 
inspectorates, who act as temporary advisers to the WHO) and WHO staff members [26].  
Discussion 
One potential solution to the above-described scenarios would be to establish individual 
bioequivalence studies including long-term efficacy (when applicable and only for certain 
drugs such as immunosuppressants) and safety follow-ups, rather than average 
bioequivalence. Post-authorisation, concerns regarding the safety in combination with the 
efficacy of a medicine, might be raised when a medicine is substituted with another (either 
“me too” or generic). This is because such concerns are related to the interchangeability of 
a medicine in a patient in treatment. Individual bioequivalence could take into account 
variances (intra-subject as well as formulation variances and their effects in subjects) as 
an important criterion potentially affecting clinical efficacy, when a generic is substituted for 
a reference product. However, individual bioequivalence remains a theoretical concept 
which has not yet been proven in clinical practice. In addition, the approval of marketing 
authorizations submitted with support from individual bioequivalence data has not been 
implemented. The statistical approach in individual bioequivalence is another important 
issue, as major efficacy and safety concerns arise due to the possible recognition of wide 
acceptance ranges.  
Another potential solution for certain cases of medicinal products could be to tighten the 
acceptance range (possibly through the tightening of only one side of the acceptance 
limits) and to establish therapeutic equivalence. However, there could be limitations of 
such a proposal (e.g. an asymmetric acceptance range of 90–125%) in clinical practice, as 
issues of interchangeability within the same patient could be of concern. Switches from the 
brand leader to the generic, vice-versa, or generic-to-generic occur in many clinical 
practice settings throughout the world and are increasingly endorsed by governments and 
third party payers. Therefore, there is a possibility that the acceptance limits for 
effectiveness would then become larger going from one product to another. In epilepsy, in 
a scenario where the generic’s confidence intervals during approval were closer to the 
80% limit, when a patient is switched from a generic to the brand leader, a greater risk for 
side effects could be created than the vice-versa case of switching from brand-leader to 
the generic. Thus, patients could have higher drug plasma concentrations when switched 
to the originator/brand leader product. Unless justified CIs of 80–125% are accepted by 
the regulators, narrowing the confidence intervals (both sides) would resolve efficacy and 
safety concerns in the above scenarios as well as when there are documented drug-
induced interactions or genetic variability that decrease a clinical response. It should be 
noted, however, that such issues have been foreseen in the guidelines and appropriate 
reference is made to narrow therapeutic index or narrow therapeutic range products. 
There may be a need to expand these narrow CI limits for additional categories of 
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medicinal products (e.g. products that have had the black symbol and have been under 
additional monitoring).  
Regulators face the challenge to impose RMMs on both brand leaders and generic 
products when their respective companies may have a different economic interest in the 
marketing of the products at stake. Originally, the company of the brand leader was the 
“owner” of the on-patent product, synergizing both responsibilities of risk minimization and 
economic benefits. After the generic switch, ‘ownership’ and economic interests became 
fragmented among multiple stakeholders. Recent EU regulations allow for the requirement 
to implement RMMs as part of the license and to set conditions to monitor the variability of 
the clinical response of licensed products, both reference products and generics. Generic 
manufacturers are in a position to be able to set and justify bioequivalence acceptance 
ranges, but is all the information publicly available to carry this out? Publishing 
assessment reports by regulators helps, while EU summaries of risk management plans 
will provide additional information. When in doubt, manufacturers could request scientific 
advice on their clinical development program.  
The EU has started issuing specific monographs for bioequivalence (similar to the FDA), 
and acceptance ranges are specified there (refer to www.ema.europa.eu). With such an 
approach, EU regulators must consider what would be the best time to prepare such 
monographs. Is it just after the originators’ licensure or after some years of clinical 
experience? Based on the data obtained (Fig. 1), we identify the period upon which 
licensure of the originator is apt since the clinical data supporting efficacy have been 
recently generated. Following that, an update to such monographs will be probably 
required two to three years before coming “off patent”, since this is expected to be on the 
crest of the knowledge base generated for the specific medicinal product.  
 
Fig. 1. Knowledge generation over time 
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Despite recent unfortunate issues with generic drug companies that have raised questions 
about quality and supply, it is our opinion that few healthcare systems have shunned the 
generics products altogether. With stepped-up international scrutiny of the industry, 
national healthcare systems continue to show confidence in generics as cost-effective 
treatment options. 
Conclusion 
This paper discusses broad, but important regulatory issues and challenges faced by 
regulators during the approval of generic medicinal products that could potentially affect 
the efficacy and safety of generic medicinal products, since the risk of licensing 
inappropriate generics may lead to public health consequences and such consequences 
cannot be withstood by the system. As a result, based on our personal experiences, we 
have discussed examples and the possibility whether partially changing the rules is 
appropriate. It should be noted that in the vast majority of instances, the current rules 
(safety and efficacy) are appropriate, but acceptance limits might need to be tightened for 
certain medicinal products, and not only due to the active substances’ narrow therapeutic 
index. Furthermore, we highlight specific scenarios with a substantial likelihood of 
occurring that could give rise to safety concerns encountered during the approval process 
of generic applications. Manufacturers should keep these aspects in mind when submitting 
a marketing authorization application. Similarly, regulators during the assessment process 
are expected to approve a generic medicinal product, which in the above scenarios could 
not always be through an easy, clear-cut decision-making process. 
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